Cue Biopharma (CUE) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month price targets for Cue Biopharma's stock. Their CUE share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.33 in the next year. This suggests a possible upside of 102.8% from the stock's current price.
View analysts price targets for CUE or view top-rated stocks among Wall Street analysts.

Cue Biopharma's stock was trading at $2.85 at the beginning of the year. Since then, CUE stock has increased by 44.2% and is now trading at $4.11.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CUE earnings forecast.

Cue Biopharma, Inc. (NASDAQ:CUE) released its earnings results on Tuesday, May, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.30 million. Cue Biopharma had a negative trailing twelve-month return on equity of 89.72% and a negative net margin of 12,005.79%.

ETFMG Treatments Testing and Advancements ETF holds 13,528 shares of CUE stock, representing 0.26% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Cue Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Prosight Management LP (2.67%), BlackRock Inc. (1.54%), Dimensional Fund Advisors LP (1.26%), Geode Capital Management LLC (1.05%), Sigma Planning Corp (0.51%) and Bank of America Corp DE (0.39%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Cameron Gray, Colin Sandercock, Daniel R Passeri, Kenneth Pienta, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CUE stock can currently be purchased for approximately $4.11.

Cue Biopharma (NASDAQ:CUE) has a market capitalization of $177.46 million and generates $432,227.00 in revenue each year. The company earns $-53,010,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.cuebiopharma.com. The company can be reached via phone at (617) 949-2680 or via email at ir@cuebio.com.